方舟股份的H2H智慧医疗平台被评为广东省十大高新技术创新产品之一-动脉网

Fangzhou Inc.'s H2H Smart Healthcare Platform Honored as one of Guangdong's Premier High-Tech Innovation Products

CISION 等信源发布 2025-03-17 15:43



可切换为仅中文







GUANGZHOU, China

中国广州

，

March 17, 2025

2025年3月17日

/PRNewswire/ -- Fangzhou Inc. ('Fangzhou' or the 'Company') (06086.HK), a leader in Internet healthcare solutions, today announced that its proprietary 'H2H Smart Healthcare Innovation Platform' has been distinguished as a '2024

/PRNewswire/ -- 方舟股份（“方舟”或“公司”）（06086.HK），互联网医疗解决方案的领导者，今日宣布其专有的“H2H智能医疗创新平台”被评为“2024

Guangdong Province

广东省

Premier High-Quality and High-Tech Product' by the Guangdong High-Tech Industry Association. This prestigious accolade underscores Fangzhou's pioneering advancements in technological innovation and leadership in shaping the digital healthcare landscape.

广东省高新技术产业协会授予的“优质高科技产品”最高奖项。这一殊荣凸显了方舟在技术创新方面的开创性进展，以及在塑造数字医疗领域方面的领导地位。

Dr. Xie Fangmin, founder, chairman, and CEO of Fangzhou, commented, 'The H2H platform's inclusion highlights our role in advancing smart healthcare through groundbreaking solutions. Fangzhou looks forward to advancing the Internet healthcare sector toward sustainable and high-impact growth, by intensifying focus on AI-driven healthcare ecosystems, fostering deeper relationships with industry stakeholders.'.

谢方民博士，方舟的创始人、董事长兼首席执行官评论道：“H2H平台的纳入凸显了我们在通过开创性解决方案推动智能医疗方面的作用。方舟期待通过加强对人工智能驱动的医疗生态系统的关注，加深与行业利益相关者的联系，推动互联网医疗领域朝着可持续和高影响力的增长方向发展。”

Pursuing Innovation in AI-Powered Healthcare

追求人工智能医疗的创新

Fangzhou continues to push the boundaries of technological excellence. In 2025, the Company successfully deployed cutting-edge AI models, leveraging DeepSeek-V3 and DeepSeek-R1, through full-scale integration and local deployment. Through its strategic collaboration with

方舟继续推动技术卓越的边界。2025年，该公司成功部署了尖端的人工智能模型，利用DeepSeek-V3和DeepSeek-R1，通过全面集成和本地部署。通过与战略合作伙伴的协作，

Tencent

腾讯

Cloud and

云和

Tencent

腾讯

Health, Fangzhou is exploring transformative AI applications across pharmaceutical logistics and healthcare services.

健康方面，方舟正在医药物流和保健服务领域探索变革性的人工智能应用。

AI Assisted Healthcare

人工智能辅助医疗保健

By harnessing its 'AI + H2H Smart Healthcare Ecosystem', Fangzhou's upgraded platform now features four flagship AI-driven modules: AI Physician Assistant, AI Customer Engagement Assistant, AI Procurement Orchestrator, and AI Content Assistant. We believe that these AI enabled applications have the potential significantly enhance efficiency across our platform, .

通过利用其“人工智能+人对人智能医疗生态系统”，方舟升级后的平台现在拥有四个旗舰级人工智能驱动的模块：人工智能医生助理、人工智能客户互动助理、人工智能采购协调员和人工智能内容助理。我们相信，这些人功智能应用有潜力大幅提升我们平台的效率。

ultimately

最终

enabling us to

使我们能够

deliver

交付

an improved user experience for our patients and customers.

为我们的患者和客户提供更好的用户体验。

About Fangzhou Inc.

关于方舟公司

Fangzhou Inc. (06086.HK) is

方舟子公司（06086.HK）是

China's

中国的

leading online chronic disease management platform. With 45.6 million registered users and 217,000 registered doctors on its platform (as of

领先的在线慢性病管理平台。截至（某日期），该平台拥有4560万注册用户和21.7万名注册医生。

June 30, 2024

2024年6月30日

), the Company provides tailored medical care and precision medicine for a growing population of chronic disease patients. For more details, visit

），公司为不断增长的慢性病患者群体提供定制化的医疗服务和精准医疗。欲了解更多信息，请访问

https://investors.jianke.com

。

About the '

关于 '

Guangdong Province

广东省

Premier High-Quality and High-Tech Product' Award

首届高品质高科技产品奖

The '

` 单引号 `

Guangdong Province

广东省

Premier High-Quality and High-Tech Product' designation celebrates innovations developed by local high-tech enterprises that exemplify proprietary intellectual property, technological sophistication, market leadership, and disruptive potential. Rigorously evaluated by industry experts, award-winning products embody .

“首批高品质高科技产品”称号表彰了由当地高科技企业开发的创新产品，这些产品体现了自主知识产权、技术复杂性、市场领导地位和颠覆性潜力。获奖产品经过行业专家严格评估，代表了行业的最高水平。

Guangdong's

广东省的

commitment to fostering a globally competitive innovation ecosystem and driving economic advancement through technological leadership.

致力于培育具有全球竞争力的创新生态系统，并通过技术领导力推动经济发展。

Media Contact

媒体联系人

For further inquiries or interviews, please reach out to:

如有进一步查询或采访需求，请联系：

Xingwei Zhao

赵兴伟

Associate Director of Public Relations Email:

公共关系副总监电子邮件：

pr@jianke.com

Disclaimer: This press release contains forward-looking statements. Actual results may differ materially from those anticipated due to various factors. Readers are cautioned not to place undue reliance on these statements

免责声明：本新闻稿包含前瞻性陈述。由于各种因素，实际结果可能与预期有重大差异。读者被提醒不要过分依赖这些陈述。

SOURCE Fangzhou Inc.

来源：方舟公司

WANT YOUR COMPANY'S NEWS

想要你公司的新闻

FEATURED ON PRNEWSWIRE.COM?

荣登PRNEWSWIRE.COM？

440k+

44万+

Newsrooms &

新闻编辑室 &

Influencers